Satoshi Wasamoto
Overview
Explore the profile of Satoshi Wasamoto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
93
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yanagisawa S, Yui T, Kozu Y, Takechi H, Wasamoto S
Eur J Cancer
. 2025 Jan;
217:115227.
PMID: 39818488
No abstract available.
2.
Yanagisawa S, Yui T, Takechi H, Wasamoto S
Clin Respir J
. 2024 Sep;
18(9):e70008.
PMID: 39225667
No abstract available.
3.
Wasamoto S, Imai H, Tsuda T, Nagai Y, Kishikawa T, Ono A, et al.
Intern Med
. 2024 May;
64(1):55-64.
PMID: 38749728
Objective Pembrolizumab plus platinum and pemetrexed (Pemb-Plt-PEM) combination therapy is an effective first-line treatment for advanced non-squamous non-small-cell lung cancer (NSCLC), regardless of programmed death-ligand 1 expression. However, the effectiveness...
4.
Nishihara-Kato F, Imai H, Tsuda T, Wasamoto S, Nagai Y, Kishikawa T, et al.
Oncology
. 2023 Aug;
102(1):30-42.
PMID: 37598676
Introduction: Pembrolizumab (Pemb) therapy in conjunction with carboplatin and paclitaxel (PTX)/nab-PTX has been efficacious in treating non-small cell lung cancer (NSCLC). However, the response predictors of this combination therapy (Pemb-combination)...
5.
Imai H, Wasamoto S, Tsuda T, Nagai Y, Kishikawa T, Masubuchi K, et al.
Thorac Cancer
. 2023 Jul;
14(25):2567-2578.
PMID: 37469246
Background: Factors predicting the response to pembrolizumab plus platinum and pemetrexed combination therapy (Pemb-Plt-PEM) in nonsquamous non-small cell lung cancer (non-sq NSCLC) are unclear. We investigated the Glasgow Prognostic (GP)...
6.
Wasamoto S, Imai H, Tsuda T, Nagai Y, Minemura H, Yamada Y, et al.
Front Oncol
. 2023 Feb;
12:1080729.
PMID: 36741711
Background: There are no established predictive biomarkers for the effectiveness of first-line atezolizumab plus carboplatin and etoposide therapy in patients with small-cell lung cancer (SCLC). Therefore, the current study aimed...
7.
Masubuchi K, Imai H, Wasamoto S, Tsuda T, Minemura H, Nagai Y, et al.
Thorac Cancer
. 2022 Sep;
13(19):2776-2785.
PMID: 36062426
Background: The effect of first-line chemotherapy on overall survival (OS) may be significantly influenced by subsequent therapy for patients with extensive disease small cell lung cancer (ED-SCLC). Therefore, we evaluated...
8.
Imai H, Nagai Y, Minemura H, Tsuda T, Yamada Y, Wasamoto S, et al.
Invest New Drugs
. 2022 Jun;
40(5):1066-1079.
PMID: 35749041
This study examined the activity and safety of amrubicin monotherapy among relapsed small-cell lung cancer (SCLC) patients who had previously been treated with atezolizumab plus carboplatin and etoposide (AteCE). This...
9.
Shiono A, Imai H, Wasamoto S, Tsuda T, Nagai Y, Minemura H, et al.
Cancer Med
. 2022 Jun;
12(1):73-83.
PMID: 35699088
Purpose: The aim of this study was to assess the effectiveness and tolerability of atezolizumab plus carboplatin and etoposide combination chemotherapy in elderly patients with extensive-disease (ED) small-cell lung cancer...
10.
Araki T, Tateishi K, Komatsu M, Sonehara K, Wasamoto S, Koyama S, et al.
Thorac Cancer
. 2022 May;
13(14):2031-2040.
PMID: 35616056
Backgrounds: The PACIFIC trial established durvalumab consolidation therapy after concurrent chemoradiotherapy (CCRT) as the standard treatment for locally advanced non-small cell lung cancer (LA-NSCLC). However, little is known about the...